Pregled bibliografske jedinice broj: 551083
Topoisomerase IIα in colorectal carcinoma: expression and prognostic role
Topoisomerase IIα in colorectal carcinoma: expression and prognostic role // Annals of Oncology 2010 ; 21 (suppl 8): viii 212-213 (662P). Abstract Book of the 35th ESMO Congress Milan, Italy, 8–12 October 2010. / 35th ESMO Congress Scientific Committee (ur.).
Milano, Italija, 2010. str. 212-213 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 551083 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Topoisomerase IIα in colorectal carcinoma: expression and prognostic role
Autori
Juretić, Antonio ; Gojević, Ante ; Jakić-Razumović, Jasminka ; Klepac-Pulanić, Tajana ; Pućo, Katarina
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Annals of Oncology 2010 ; 21 (suppl 8): viii 212-213 (662P). Abstract Book of the 35th ESMO Congress Milan, Italy, 8–12 October 2010.
/ 35th ESMO Congress Scientific Committee - , 2010, 212-213
Skup
35th ESMO Congress Milan, Italy, 8–12 October 2010.
Mjesto i datum
Milano, Italija, 08.10.2010. - 12.10.2010
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
colorectal cancer; topoisomera IIalpha
(colorectal cancer; topoisomerase IIalpha)
Sažetak
Aim and background: Since very few data have been published, the aim of this study was to investigate the expression and prognostic role of topoisomerase IIa in patients with colorectal cancer (CRC). Patients and methods: The expression of topo IIa was evaluated immunohistochemically (IHC) on archival paraffin-embedded samples of CRC tissue from 146 patients, 59 (40.4%) females and 87 (59.6%) males, operated on in our hospital at Department of Surgery. Their median age was 65 years (range 35-87). There were 32 (22.1%) Dukes A, 46 (31.7%) Dukes B, 46 (31.7%) Dukes C tumors and 21(14.5%) tumors with distant metastasis. IHC was carried out by using the MoAb anti-human TOPO-IIa antibody (DAKO No K 0355). Immunoreactivity was scored semiquantitatively so that patients could be divided into the three groups according to the percentage of tumor cells staining topo IIa positive: group 1 (£ 10% ; n = 10 (7%)), group 2 (11-50% ; n = 85 (58%)) and group 3 (>50% ; n = 51 (35%)). Obtained IHC results were correlated with the following clinicopathological parameters: tumor stage (Dukes classification), tumor grade, vascular invasion and patients survival. All results are expressed as median (range). Results: The follow up period was 72 (0-95) months. A trend toward statistically significant worse survival was observed for the patient group 1 (30%) comparing to group 2 (57.6%) and group 3 (51.0%), but result was not statistically significant (30% vs 57.6%, p = 0.051 ; 30% vs 51%, p = 0.131). Toppo IIa expression was not found to be statistically different among patients arranged according to the Dukes tumor stage (Dukes A = 35% ; B = 35% ; C = 32.5% ; tumor stage with distant metastases = 40%). Also, there was no significant correlation between the topo IIa expression and tumor grade (g) (g 1 = 40%, g 2 = 35%, g 3 = 35%), vascular invasion (without = 35%, with = 40%) and lymph node affection (N0 = 35%, N+ = 40%). Conclusion: No significant correlation between the mentioned clinicopathologic parameters and the topo IIa was identified. The only exception were the patients’ survival data which showed worse survival in patients with lower expression of topo IIa, but without statistical significance. Due to relative rarity of this type of research, additional studied in larger cohort of patient are needed.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
214-0000000-3601 - Učinak zračenja u bolesnika s rakom prostate na Tregs-limfocite (Juretić, Antonio, MZOS ) ( CroRIS)
Ustanove:
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE